Based on our work starting up COVID-19 studies, we provide recommendations to shave time from your startup timelines.
| This week's FierceBiotech is brought to you by Rho.
Trouble viewing? Click here. |
| | | | | | | Dear E, When developing and testing potential COVID-19 therapies in patient populations, startup of your clinical trial must be efficient while still taking into account the complexities of this uncertain research landscape. Based on our work with sponsors who have been starting up COVID-related studies, we can provide recommendations to shave time from your startup timelines and set your program up for success from the beginning. In this article, Rho experts discuss considerations for starting your COVID-19 clinical trial quickly. Topics covered include: Site selection Site monitoring Data management Planning and documentation Team communication Considering the challenges detailed in the article earlier and planning your COVID-19 trial to account for them will increase your likelihood of a successful and rapid start-up and will help ensure a high-quality clinical trial in this complex research landscape. Please contact me if you have any questions or would like to speak to one of our experts about your COVID-19 clinical trial. Best, Lisa Payne |
| | |
|
| | |
|
If you no longer wish to receive communications from Rho, please opt out here.
Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.
You are currently subscribed as newsletter@newslettercollector.com.
If you no longer wish to receive communications from FierceBiotech's trusted partners, simply click here to unsubscribe.
Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
